![4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders](/docs/US/2023-09-12/US11753419B2/abs.jpg.600x600.jpg)
- Patent Title: 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
-
Application No.: US17757212Application Date: 2020-12-10
-
Publication No.: US11753419B2Publication Date: 2023-09-12
- Inventor: Peng Li , Robert E Davis , Kimberly Vanover
- Applicant: INTRA-CELLULAR THERAPIES, INC.
- Applicant Address: US NY New York
- Assignee: INTRA-CELLULAR THERAPIES, INC.
- Current Assignee: INTRA-CELLULAR THERAPIES, INC.
- Current Assignee Address: US NY New York
- Agency: Hoxie & Associates LLC
- International Application: PCT/US2020/064338 2020.12.10
- International Announcement: WO2021/119334A 2021.06.17
- Date entered country: 2022-06-10
- Main IPC: A61K31/4985
- IPC: A61K31/4985 ; C07D471/22 ; C07D487/22 ; C07D519/00
![4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders](/abs-image/US/2023/09/12/US11753419B2/abs.jpg.150x150.jpg)
Abstract:
The invention relates to a particular substituted heterocycle fused gamma carboline, the compound of Formula I,
and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.
and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.
Public/Granted literature
- US20230021717A1 ORGANIC COMPOUND Public/Granted day:2023-01-26
Information query
IPC分类:
